<?xml version='1.0' encoding='utf-8'?>
<document id="24042856"><sentence text="NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure?" /><sentence text="Management guidelines for drug-drug interactions between non-steroidal anti-inflammatory drugs (NSAIDs) and antihypertensives recommend blood pressure monitoring in hypertensive patients" /><sentence text=" We measured the short-term effect of initiating NSAIDs on systolic blood pressure (SBP) in users of antihypertensives, aiming to investigate which outpatients are at risk for an increase in SBP in daily clinical practice" /><sentence text="" /><sentence text="A cohort study with a nested case-control design in Dutch community pharmacies" /><sentence text="" /><sentence text="Patients with a drug-drug interaction alert for a newly initiated NSAID and antihypertensive were interviewed and their SBP was measured at T0, after one week (T1) and after two weeks (T2)" /><sentence text=" We evaluated risk factors for exceeding a predefined limit of change (PLoC) in SBP (≥ 10 mmHg to ≥ 140 mmHg) at T1 and T2 versus T0" /><sentence text="" /><sentence text="For 112 patients the SBP at T0 was measured" /><sentence text=" Two patients were excluded (T0 SBP ≥ 180 mmHg)" /><sentence text=" PLoC was exceeded in 10 patients (10" /><sentence text="4%) at T1 and in seven patients (8" /><sentence text="0%) at T2" /><sentence text=" Patients using etoricoxib (odds ratio (OR), 21"><entity charOffset="16-26" id="DDI-PubMed.24042856.s15.e0" text="etoricoxib" /></sentence><sentence text="0; 95% confidence interval (CI), 3" /><sentence text="7-120" /><sentence text="6) and patients using &gt;1 defined daily dose of an NSAID (OR, 3" /><sentence text="3; 95% CI, 1" /><sentence text="1-10" /><sentence text="0) were at increased risk of a rise in SBP" /><sentence text="" /><sentence text="A newly initiated NSAID has an immediate clinically relevant effect on SBP in some users of antihypertensives" /><sentence text=" Management guidelines for NSAID-antihypertensive drug-drug interactions should advise SBP monitoring before and after initiation of an NSAID or intensification of NSAID therapy" /><sentence text=" Monitoring is especially relevant in patients prescribed high dosages of NSAIDs" /><sentence text=" Etoricoxib should not be used in hypertensive patients"><entity charOffset="1-11" id="DDI-PubMed.24042856.s26.e0" text="Etoricoxib" /></sentence><sentence text="" /></document>